Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

MG1111

PreclinicalBiologic

GGC Biopharma Corp

MG1111 is one of 42 biologic programs targeting Children. It is currently in Preclinical.

1

Indications

4

Total Trials

2

Active Trials

41

Competitors

Pipeline

Status by Indication[3][1]

Indication

ChildrenUnknown status

ChildrenPreclinical

Unknown status

Competition

Competitive Landscape

58 competitors in Children

#DrugCompanyPhaseTrials

Promacta

Gleevec

Ozempic

Oncaspar

Sprycel

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Velcade

SShilpa Grover, MD, MPH

Byetta

Neurontin

VViatris Specialty LLC

Somavaratan

Xyrem

Jazz Pharmaceuticals

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 2Recruiting

Immunogenicity

NCT05422508

Q3 2036

Phase 3Not yet recruiting

Immunogenicity

NCT07054099

Clinical

Trials by Indication[1]

Immunogenicity2 trials

Evaluate the Safety and Immunogenicity After MG1111(BARICELA Inj.) as 2nd Vaccination in 4 ~ 6 Year Old Healthy Children With a History of 1st Varicella Vaccination

Recruiting·GGreen Cross Corporation·Phase 2·NCT05422508·230 enrolled

A Study to Evaluate Immunogenicity and Safety After the First and Second Doses of MG1111 (BARYCELA Inj.) in Healthy Children Aged 12 Months to 12 Years

Not yet recruiting·GGC Biopharma Corp·Phase 3·NCT07054099·474 enrolled

Children1 trial

An Open-label, Bridging Study of BARYCELA Inj. in Healthy Vietnamese Children Aged Between 12 Months to 12 Years

Unknown status·GGC Biopharma Corp·N/A·NCT05664152·250 enrolled

Safety and Efficacy1 trial

Dose-escalation Phase 1 to Evaluate the Safety and Efficacy of MG1111 in Healthy Adults

Completed·GGreen Cross Corporation·Phase 1·NCT02367638·39 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for MG1111. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — MG1111 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for MG1111. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — GC Biopharma Corp company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Preclinical[1]
Company: GGC Biopharma Corp

Related News